Longfellow Investment Management Co. LLC Has $1.47 Million Position in Johnson & Johnson $JNJ

Longfellow Investment Management Co. LLC grew its position in Johnson & Johnson (NYSE:JNJ) by 23.9% during the 2nd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 9,635 shares of the company’s stock after purchasing an additional 1,858 shares during the period. Longfellow Investment Management Co. LLC’s holdings in Johnson & Johnson were worth $1,472,000 as of its most recent filing with the SEC.

A number of other hedge funds have also made changes to their positions in JNJ. Brighton Jones LLC increased its holdings in Johnson & Johnson by 13.9% during the 4th quarter. Brighton Jones LLC now owns 51,876 shares of the company’s stock valued at $7,502,000 after purchasing an additional 6,332 shares in the last quarter. Wealth Group Ltd. acquired a new position in Johnson & Johnson during the 1st quarter worth about $218,000. Smart Money Group LLC increased its position in Johnson & Johnson by 6.5% in the 1st quarter. Smart Money Group LLC now owns 6,687 shares of the company’s stock valued at $1,109,000 after acquiring an additional 407 shares in the last quarter. United Bank lifted its position in shares of Johnson & Johnson by 110.7% during the first quarter. United Bank now owns 9,279 shares of the company’s stock worth $1,539,000 after purchasing an additional 4,876 shares in the last quarter. Finally, Assetmark Inc. grew its stake in shares of Johnson & Johnson by 8.2% during the first quarter. Assetmark Inc. now owns 85,662 shares of the company’s stock valued at $14,206,000 after purchasing an additional 6,501 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Insider Buying and Selling

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of Johnson & Johnson stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the transaction, the executive vice president owned 178,013 shares of the company’s stock, valued at approximately $31,652,491.53. The trade was a 24.08% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Company insiders own 0.16% of the company’s stock.

Johnson & Johnson Stock Performance

Shares of JNJ stock opened at $203.88 on Monday. The stock has a market cap of $491.21 billion, a PE ratio of 19.68, a price-to-earnings-growth ratio of 2.19 and a beta of 0.38. The stock has a 50-day moving average of $188.25 and a 200-day moving average of $171.78. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.07 and a quick ratio of 0.80. Johnson & Johnson has a one year low of $140.68 and a one year high of $206.94.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. The company had revenue of $24.02 billion for the quarter. As a group, sell-side analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 9th. Investors of record on Tuesday, November 25th will be given a $1.30 dividend. The ex-dividend date is Tuesday, November 25th. This represents a $5.20 annualized dividend and a dividend yield of 2.6%. Johnson & Johnson’s payout ratio is currently 50.19%.

Analysts Set New Price Targets

A number of research analysts have commented on JNJ shares. Citigroup increased their price objective on Johnson & Johnson from $213.00 to $215.00 and gave the company a “buy” rating in a research report on Wednesday, October 15th. Bank of America lifted their price objective on Johnson & Johnson from $198.00 to $204.00 and gave the stock a “neutral” rating in a research report on Wednesday, October 15th. Raymond James Financial upped their target price on shares of Johnson & Johnson from $174.00 to $209.00 and gave the company an “outperform” rating in a research report on Wednesday, October 15th. HSBC lifted their price target on shares of Johnson & Johnson from $210.00 to $215.00 and gave the stock a “buy” rating in a research report on Thursday, October 16th. Finally, Daiwa Capital Markets raised shares of Johnson & Johnson from a “neutral” rating to an “outperform” rating and set a $203.00 price objective on the stock in a research note on Monday, October 20th. Four research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and nine have given a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $201.05.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.